Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13690302 | 0.86 | MCL1 (0.49) | TP53TSHRSMN1; SMN2KDM4EHPGD | |
| SCHEMBL7884857 | 0.85 | KMT2A (0.47) | TP53SMN1; SMN2GAAKDM4ECRHBP | |
| SCHEMBL4054227 | 0.83 | SRD5A2 (0.47) | SMN1; SMN2MAOAKDM4ECRHBPCRHR2 | |
| SCHEMBL14276252 | 0.80 | KMT2A (0.50) | TP53SMN1; SMN2GAAKDM4ECRHBP | |
| SCHEMBL14276278 | 0.80 | ACHE (0.50) | SMN1; SMN2KDM4ECRHBPCRHR2NPC1 | |
| SCHEMBL3160370 | 0.79 | CA12 (0.53) | SMN1; SMN2MAOAGAAKDM4ECRHBP | |
| SCHEMBL7884252 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2KDM4ECRHBPCRHR2NPC1 | |
| SCHEMBL5125297 | 0.78 | KDM4E (0.45) | TSHRSMN1; SMN2GAAKDM4ECRHBP | |
| SCHEMBL3565037 | 0.78 | KDM4E (0.45) | TSHRSMN1; SMN2GAAKDM4ECRHBP | |
| SCHEMBL7285824 | 0.78 | NOD2 (0.46) | TP53TSHRSMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592332-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090023701-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2009-01-22 | — | — | US | disclosed |
| EP-1867646-A1 | Cytokine inhibitors | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070275946-A1 | Cytokine Inhibitors | AUNGST RONALD A | 2007-11-29 | — | — | US | disclosed |
| US-7285545-B2 | N-Pyridyl-7-substituted-2-indolecarboxamides, e.g., 1-Methyl-7-[2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yloxy]-1H-indole-2-carboxylic acid (2-tert-butyl-5-methoxy-pyridin-4-yl)-amide; used to treat chronic inflammatory diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023701-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | TP53 3085/4885TSHR 3979/4885SMN1; SMN2 4459/4885 |
| US-20070275946-A1 | Cytokine Inhibitors | IL1B, TNF, IL1A | TP53 3085/4885TSHR 3979/4885SMN1; SMN2 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.